Compare Cassava Sciences Inc (FLNA) vs J M Smucker Co (SJM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs J M Smucker Co — how do they compare? Cassava Sciences Inc trades at $1.1 (market cap $53.14M), while J M Smucker Co trades at $109.02 (market cap $11.65B). The key difference: J M Smucker Co is far larger — about 219.2× Cassava Sciences Inc's market cap, and J M Smucker Co pays a 4.04% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | SJM | |
|---|---|---|
Market Cap | $53.14M | $11.65B |
Sector | Health | Consumer Staples |
52-Week High | $4.64 | $117.05 |
52-Week Low | $1.09 | $89.53 |
Enterprise Value | -$33.43M | $18.68B |
Dividend Yield | — | 4.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
J.M. Smucker (SJM) trades at $113.00, up 3.85% today, with a bearish technical signal despite recent earnings beats. The company reported a net loss of $1.23 billion for 2025, with negative profit margins, though revenue grew to $8.73 billion. Analyst consensus is a Buy with a $123.18 price target, supported by strong cash flow and a 4% dividend yield. Key growth drivers include Uncrustables and coffee brands, while fiscal 2027 sales are expected to decline 3-4%.
SJM presents a mixed outlook: valuation appears reasonable with a P/E of 22.05, but profitability concerns and high debt pose risks. Near-term catalysts include cost controls and brand innovation, yet competitive pressures and weak sales guidance may limit upside. The stock offers income via dividends, but investors should weigh execution risks against potential margin recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About J M Smucker Co
J.M. Smucker is a packaged food company that primarily operates in the U.S. retail channel (87% of fiscal 2022 revenue), but also in U.S. food-service (7%), and international (6%). Its largest segment is pet food and treats (36% of 2022 revenue), with popular brands such as Milk-Bone, Meow Mix, 9Lives, Kibbles 'n Bits, Nature's Recipe, and Rachael Ray Nutrish. Its second-largest category is coffee (35% across channels) with the number-two brand Folgers and number-six Dunkin'. Other large categories are peanut butter (10%), with number-one Jif, fruit spreads (5%) with number-one Smucker's, and frozen hand-held foods (6%) with number-one Uncrustables.
Read more on SJM →
